Clinical Research Library & Scientific Monographs
Peer-reviewed technical overviews, CRISPR-Cas endonuclease mechanisms, mRNA delivery formulation chemistries, and allogeneic cellular immunotherapy research protocols.
Epigenetic Reprogramming & Yamanaka Factors: Cellular Rejuvenation Without Teratoma Formation
Master in vivo epigenetic reprogramming: Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), Horvath DNA methylation clock reversal, and cyclic teratoma-free rejuvenation.
Allogeneic CAR-NK Cell Therapy: Overcoming Solid Tumor Immunosuppression & Off-the-Shelf Manufacturing
Master allogeneic CAR-NK cell therapies: zero Graft-versus-Host Disease (GvHD), CD16/NKG2D dual-targeting, TGF-beta tumor microenvironment defense, and iPSC bioreactors.
Lipid Nanoparticles (LNPs) for mRNA Delivery: Ionizable Lipids, Formulation Chemistry & Biodistribution
In-depth guide to lipid nanoparticle (LNP) formulation for mRNA therapeutics: ionizable cationic lipids, helper phospholipids, cholesterol, and PEG-lipid optimization.
CRISPR-Cas9 vs. Cas12 vs. Cas13: Molecular Mechanisms, PAM Requirements & Target Specificity
Comprehensive molecular comparison of CRISPR-Cas9, Cas12a, and Cas13 nucleases. Explores PAM motifs, staggered vs blunt cuts, collateral cleavage, and in vivo therapeutic utility.
Optimizing CRISPR-Cas24 for Hepatocyte Target Interception
Discover how our high-fidelity CRISPR-Cas24 editor achieves 94% gene silencing efficiency inside hepatocytes, preventing off-target double-stranded breaks.
BioModifying - Cellular Therapeutics for Next-Gen Oncology & Gene Editing
BioModifying is a clinical-stage biopharmaceutical organization developing CRISPR gene editing and CAR-NK cellular therapeutics for next-gen oncology.
Translating mRNA Therapeutics: Overcoming Immunogenic Obstacles
Learn how chemical modification of mRNA transcripts with pseudouridine variations evades innate cellular defenses and extends therapeutic translation cycles.